“For MSD, research is a real vocation: this is demonstrated by the data on investments by pharmaceutical multinationals in the last year. According to this ranking, we at MSD stand in first place with 30.6 billion dollars of investment in the sector alone. 2023, in inventions, in research and development, in everything that is innovation in the field of medicine, not just in oncology. In second place is another pharmaceutical company that can boast half of what we have invested in 2023 alone. A commitment. therefore very strong: for us research means innovative drugs, investing in vaccines for different forms of cancer and for the human papilloma virus (HPV), as well as for prevention”. Nicoletta Luppi, president and CEO of MSD Italia, told Adnkronos Salute today in Rome on the sidelines of the presentation of the national awareness campaign ‘They are not all the same. Breast cancer and life paths’.
The social initiative is promoted by Msd Italia in collaboration with the Aiom Foundation (Italian Association of Medical Oncology), Anisc (Italian National Association of Breast Surgeons), Aps Senonetwork Italia (the network of Italian breast centers), Sipo (Italian Society of Psycho-Oncology ), Aps Susan G. Komen Italia and the patient associations Europa Donna Italia, Fondazione IncontraDonna and Salute Donna OdV, with the recognition of Sirm (Italian Society of Medical and Interventional Radiology).
#Luppi #MSD #billion #dollars #invested #RD2
